Volumen: 17 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2013
90Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin s Lymphoma. Multi-institutional Argentinian Study
Authors: Cacchione R, Dupont J, Milone J, Bordone J, Basso A, Castro Rios M, Milone G, Tur R, Anselmo A, Argentieri D, Negri P, Fedeles J, Campo C, Alzueta A, Chiattone C, Shanley C, Garay G, Ardaiz M, Lafalle D, Prates M, Avila G, Iabstrebner M, Rudoy S, Riera L, Pombo G, Tartas N, Fantl D, Caffaro M, Riveros D, Brown M, Palmer L, Díaz A, Ponzinibbio C, Zopegno L, de Tezanos Pinto M, Bartomioli M, Trouboul A, Furque M, Cazap N y Bezares R
Abstract: The radionucleid conjugate with monoclonal antibodies (antiCD20/90Y-ibritumomab tiuxetan) has been approved for the treatment of relapsed, refractory and transformed (high grade) follicular lymphomas. Between September
2005 and March 2012, 62 patients with refractory/relapsed lymphoma were enrolled. Median age was 61 yrs old (41-83). 90Y-Ibritumomab (Zevamab TM Bayer-Schering Argentina) was administered at 0.3 or 0.4 mCi, based on initial platelet count. Global response at 3rd month was 79% with CR of 55%. At 48 months the progression
free survival and overall survival were 32% and 42% respectively. Hematological toxicity was present in 15 pts, in 14 was reversible and transitory, and one patient died of bone marrow aplasia.
These results place the radioimmunoconjugates among the options to treat relapsed patients with multiple lines of chemoimmunotherapy.
Key words: NO Hodgkyn lymphoma; 90Y-Ibritumomab
radioimmunoconjugates; radioinmmunotherapy
Pages : 238-242
|
